Acute or adult respiratory distress syndrome (ARDS) was first described in the 1960s<sup>7 Ashbaugh D.G., Bigelow D.B., Petty T.L. , y al. Acute respiratory distress in adults Lancet 1967 ;  2 : 319  [cross-ref]

Haga clic aquí para ir a la sección de Referencias</sup> and was recently reviewed.<sup>101 Kollef M.H., Schuster D.P. The acute respiratory distress syndrome N Engl J Med 1995 ;  332 : 27  [cross-ref]

Haga clic aquí para ir a la sección de Referencias</sup> The medical treatment of this syndrome has been largely directed at ventilatory and general supportive care. The recent slight reduction in the historic 50% mortality rate for ARDS has been attributed to advances in respiratory care.<sup>102 Krafft P., Fridrich P., Pernerstorfer T. , y al. The acute respiratory distress syndrome: Definitions, severity and clinical outcome. An analysis of 101 clinical investigations Intensive Care Med 1996 ;  22 : 519  [cross-ref]

Haga clic aquí para ir a la sección de Referencias</sup>

In this article, pharmacologic attempts at mitigating the severity of presentation or preventing the development of ARDS are discussed. Specifically, clinical trials examining the therapeutic effects of ketoconazole, antioxidants, corticosteroids, surfactant, ketanserin, pentoxifylline, bronchodilators, and almitrine on the development or manifestation of ARDS are reviewed. Further aspects of current animal data, basic science, proposed mechanism of actions, and supporting clinical trials are critically reviewed. Pulmonary vasodilators, (i.e., prostacyclin and prostaglandin E₁), inhaled nitric oxide, new techniques for ventilation, extracorporeal approaches to the removal of carbon dioxide and the supplementation of oxygen, and techniques in which partial liquid ventilation with perfluorocarbons are used are covered in other articles in this publication.